at China Focus@ San Francisco is open now!
– China’s Leading Companies
– Global Pharma Companies
- Exclusive Partnering Consultation
- Immediate Ad-Hoc Meetings:
- Post-event follow-ups:
Unable to meet all the interested parties in one day? Rest assured. As the special privilege of presenting companies, we will continue connecting you to the companies after the event.
Get in on the action! Secure the most efficient approach to propel your China Strategies.
6 Dimensions Capital: 6 Dimensions Capital was established in 2017 by a team of prominent and experienced professionals to create a leading global investment firm with a focus on innovative life science companies in China and the United States. Currently managing 7 Funds with total assets under management over 10B RMB ($1.5B USD)
Lilly Asia Ventures (LAV): a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto, managing over $1.2 billion of committed capital. LAV has significant resources in China, with extensive local expertise in preclinical and clinical development, regulatory know-how, and market insights.
Qiming Venture Partners: Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management.
KAITAI CAPITAL: founded in 2009, KAITAI is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc. Currently, the asset under management of KAITAI CAPITAL has reached 50 billion RMB (USD$7.2B).
Morningside Group: a private investment group founded in 1986. It invests in private equity and venture capital opportunities in North America, Europe, and the Asia Pacific. Morningside Group has investments in the following sectors — machinery manufacturing, high-tech, media, telecommunication, life science, education, and cleantech. The group is managed by experienced investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate.
Hengrui Pharmaceuticals: A leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017 and a market cap of $31 billion.
Fosun Pharma: Established innovative chemical drugs platform, biologics platform, high-value generic drugs platform, and cell-therapy platform.
CSPC: Recognized as the top brand for its compliance culture, ethical business, and innovation.
Luye Pharma: an international pharmaceutical company with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas.
CStone Pharmaceuticals: a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicine to address the unmet medical needs of cancer patients.
During the 2020 JP Morgan Healthcare Conference, GenScript Biotech Global Forum will be taking place on, January 14, at Grand Hyatt San Francisco, U.S.
Under the theme of "Cell & Gene Therapy and Booming China Market", the conference aims to build a bridge between the cell & gene therapy industry and capital community, accelerating the mutual understanding and creating collaboration opportunities worldwide.
Please click here for more information.